Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453252 | Leukemia Research | 2018 | 8 Pages |
Abstract
A seven-color panel was used to detect minimal residual disease (MRD) in T cell acute lymphoblastic leukemia (T-ALL) via flow cytometry (FCM). Its availability and clinical significance were studied in T-ALL patients with newly diagnosed (nâ¯=â¯64), relapsed (nâ¯=â¯48) and morphologically complete remission (nâ¯=â¯103). The following four features were used to identify immature cCD3+ T cells: CD34+, TdT+, but mCD3-/dim+, and CD45dim+. Among these features, either TdT or CD34 expression was the most useful and were found in 93.8% of patients at diagnosis and 86.7% of patients who relapsed. Although some of the immature markers had disappeared in 23 of 59 cases after therapy, only one case presented with a false negative MRD. Of the 74 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), MRD-positive patients showed a higher relapse rate, a higher cumulative incidence of relapse at 4 years and a shorter median relapse-free survival than MRD-negative patients at post-HSCT(72.7% vs 17.3%, Pâ¯=â¯0.000; 100% vs 19.9%, Pâ¯<â¯0.0001; and 16 months vs undefined, Pâ¯<â¯0.0001). We demonstrated that this panel could be applied to>97% of T-ALL patients to detect MRD and predict relapse after allo-HSCT even in the absence of the initial immunophenotype.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ya-Zhe Wang, Le Hao, Yan Chang, Qian Jiang, Hao Jiang, Le-Ping Zhang, Ling-Ling He, Xiao-Ying Yuan, Ya-Zhen Qin, Xiao-Jun Huang, Yan-Rong Liu,